Prescribing information

 

_

Cosentyx is indicated for the treatment of: moderate to severe plaque psoriasis (PsO) in adults, adolescents and children from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis in adult patients, alone or in combination with MTX, when the response to previous DMARD therapy has been inadequate; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated CRP and/or MRI evidence in adults who have responded inadequately to NSAIDs.

Image with the words Take control early with Cosentyx to help your adult PsO patients look, move and feel better

Image with the words Real-world evidence from BADBIR, one of the largest national psoriasis registries in the world

Image with the words Recommended by BAD as the first-line biologic for patients with PsO, with or without PsA

 

What difference can Cosentyx make for your adult patients?

With over 500,000 patients treated with Cosentyx* (across all indications) since launch,1 Cosentyx offers fast and long-lasting improvements so your patients can:

 

 

How does Cosentyx inhibit IL-17A?

Watch this video which explains the Cosentyx mechanism of action and uncovers why targeting IL-17A is a key consideration when choosing a treatment for systemic inflammatory diseases such as PsO and PsA.

 

 

Click here for Cosentyx® (secukinumab) prescribing information

 
 
 

*Worldwide, across all licensed indications.1

BAD, British Association of Dermatologists; BADBIR, British Association of Dermatologists Biologic and Immunomodulators Register; CRP, C-reactive protein; DMARD, disease-modifying anti-rheumatic drugs; IL, interleukin; MRI, magnetic resonance imaging; MTX, methotrexate; NICE, National Institute for Health and Care Excellence; NSAIDs, non-steroidal anti-inflammatory drugs; PASI, Psoriasis Area and Severity Index (PASI); PsA, psoriatic arthritis; QoL, quality of life.

References

  1. Rheumatology DOF UK 313.  
  2. Cosentyx Summary of Product Characteristics.
  3. Yiu ZZN, et al. Br J Dermatol 2020;2020;183(2):294–302.     
  4. Smith CH, et al. Br J Dermatol 2020;183(4):628–637.     
  5. Thaci D, et al. J Am Acad Dermatol 2015;7(3):400–409.     
  6. Langley RG, et al. NEJM 2014;371(4):326–338.     
  7. Blauvelt A, et al. J Am Acad Dermatol 2017;76(1):60–69.     
  8. Bissonnette R, et al. J Eur Acad Dermatol Venereol 2018;32:1507–1514.     
  9. Rheumatology DOF UK 215.     
  10. Mease P, et al. Ann Rheum Dis 2018;77(6);890–897.     
  11. Mease P, et al. ACR Open Rheum 2020;2(1):18–25.     
  12. Baraliakos X, et al. RMD Open 2019;5(2):e001005.     
  13. Feldman SR, et al. J Derm Treat 2020; doi:10.1080/09546634.2019.1708854.

 

Rate this content: 
No votes yet
UK | November 2021 | 158787
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via uk.patientsafety@novartis.com or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at medinfo.uk@novartis.com